Intestinal microbiota dysbiosis in acute kidney injury: novel insights into mechanisms and promising therapeutic strategies

References

• Agarwal A, Dong Z, Harris R, et al;Acute Dialysis Quality Initiative XIII Working Group. Cellular and molecular mechanisms of AKI. J Am Soc Nephrol. 2016;27(5):1288–1299.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43(6):816–828.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cai J, Tang C, et al. Mitophagy in acute kidney injury and kidney repair. Cells. 2020;9(2):338.
   PubMed Web of Science ®Google Scholar
• He L, Wei Q, Liu J, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92(5):1071–1083.
   PubMed Web of Science ®Google Scholar
• Wilson FP, Yang W, Machado CA, et al. Dialysis versus nondialysis in patients with AKI: a propensity-matched cohort study. Clin J Am Soc Nephrol. 2014;9(4):673–681.
   PubMed Web of Science ®Google Scholar
• Tilg H, Adolph TE, Gerner RR, et al. The intestinal microbiota in colorectal cancer. Cancer Cell. 2018;33(6):954–964.
   PubMed Web of Science ®Google Scholar
• Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65(12):2035–2044.
   PubMed Web of Science ®Google Scholar
• Torres-Fuentes C, Schellekens H, Dinan TG, et al. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017;2(10):747–756.
   PubMed Web of Science ®Google Scholar
• Bao N, Chen F, Dai D. The regulation of host intestinal microbiota by polyphenols in the development and prevention of chronic kidney disease. Front Immunol. 2019;10:2981.
   PubMed Web of Science ®Google Scholar
• Li L, Ma L, Fu P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Dev Ther. 2017;11:3531–3542.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ankawi G, Sun J, et al. Gut–kidney crosstalk in septic acute kidney injury. Crit Care. 2018;22(1):117.
   Google Scholar
• Arrieta M-C, Stiemsma LT, Amenyogbe N, et al. The intestinal microbiome in early life: health and disease. Front Immunol. 2014;5:427.
   PubMed Web of Science ®Google Scholar
• Zheng HJ, Guo J, Jia Q, et al. The effect of probiotic and synbiotic supplementation on biomarkers of inflammation and oxidative stress in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;142:303–313.
   PubMed Web of Science ®Google Scholar
• Consortium THMP. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214.
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638.
   PubMed Web of Science ®Google Scholar
• Meddings J. The significance of the gut barrier in disease. Gut. 2008;57(4):438–440.
   PubMed Web of Science ®Google Scholar
• Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut. 2020;69(12):2232–2243.
   PubMed Web of Science ®Google Scholar
• Mishima E, Ichijo M, Kawabe T, et al. Germ-free conditions modulate host purine metabolism, exacerbating adenine-induced kidney damage. Toxins (Basel). 2020;12(9):547.
   PubMed Web of Science ®Google Scholar
• Andrianova NV, Popkov VA, Klimenko NS, et al. Microbiome-metabolome signature of acute kidney injury. Metabolites. 2020;10(4):142.
   PubMed Web of Science ®Google Scholar
• Knauf F, Brewer JR, Flavell RA. Immunity, microbiota and kidney disease. Nat Rev Nephrol. 2019;15(5):263–274.
   PubMed Web of Science ®Google Scholar
• Yarandi SS, Kulkarni S, Saha M, et al. Intestinal bacteria maintain adult enteric nervous system and nitrergic neurons via toll-like receptor 2-induced neurogenesis in mice. Gastroenterology. 2020;159(1):200–213.e208.
   PubMed Web of Science ®Google Scholar
• De Vadder F, Grasset E, Mannerås Holm L, et al. Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks. Proc Natl Acad Sci U S A. 2018;115(25):6458–6463.
   PubMed Web of Science ®Google Scholar
• Pahl MV, Vaziri ND. The chronic kidney disease – colonic axis. Semin Dial. 2015;28(5):459–463.
   PubMedGoogle Scholar
• Chen Y-Y, Chen D-Q, Chen L, et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17(1):5.
   PubMedGoogle Scholar
• Chung S, Barnes JL, Astroth KS. Gastrointestinal microbiota in patients with chronic kidney disease: a systematic review. Adv Nutr. (Bethesda, MD), 2019;10(5):888–901.
   PubMed Web of Science ®Google Scholar
• Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, et al. The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother. 2017;93:412–419.
   PubMed Web of Science ®Google Scholar
• Li J, Yang X, Zhou X, et al. The role and mechanism of intestinal flora in blood pressure regulation and hypertension development. Antioxid Redox Signal. 2021;34(10):811–830.
   PubMed Web of Science ®Google Scholar
• Fang Q, Liu N, Zheng B, et al. Roles of gut microbial metabolites in diabetic kidney disease. Front Endocrinol. 2021;12:636175.
   PubMed Web of Science ®Google Scholar
• Barrios C, Beaumont M, Pallister T, et al. Gut-microbiota-metabolite axis in early renal function decline. PloS One. 2015;10(8):e0134311.
   PubMed Web of Science ®Google Scholar
• Ambruzs JM, Larsen CP. Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am. 2018;44(4):699–714.
   PubMed Web of Science ®Google Scholar
• McCarthy DD, Kujawa J, Wilson C, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest. 2011;121(10):3991–4002.
   PubMed Web of Science ®Google Scholar
• Lee SA, Cozzi M, Bush EL, et al. Distant organ dysfunction in acute kidney injury: a review. Am J Kidney Dis. 2018;72(6):846–856.
   PubMed Web of Science ®Google Scholar
• Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657–670.
   PubMed Web of Science ®Google Scholar
• Gong J, Noel S, Pluznick JL, et al. Gut microbiota-kidney cross-talk in acute kidney injury. Semin Nephrol. 2019;39(1):107–116.
   PubMed Web of Science ®Google Scholar
• Noel S, Martina-Lingua MN, Bandapalle S, et al. Intestinal microbiota-kidney cross talk in acute kidney injury and chronic kidney disease. Nephron Clin Pract. 2014;127(1–4):139–143.
   PubMedGoogle Scholar
• Nakade Y, Iwata Y, Furuichi K, et al. Gut microbiota-derived D-serine protects against acute kidney injury. JCI Insight. 2018;3(20):e97957.
   PubMed Web of Science ®Google Scholar
• Yang J, Kim CJ, Go YS, et al. Intestinal microbiota control acute kidney injury severity by immune modulation. Kidney Int. 2020;98(4):932–946.
   PubMed Web of Science ®Google Scholar
• Rabb H, Pluznick J, Noel S. The microbiome and acute kidney injury. Nephron. 2018;140(2):120–123.
   PubMed Web of Science ®Google Scholar
• Lassenius MI, Pietiläinen KH, Kaartinen K, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care. 2011;34(8):1809–1815.
   PubMed Web of Science ®Google Scholar
• Park SW, Chen SWC, Kim M, et al. Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy. Lab Invest. 2011;91(1):63–84.
   PubMed Web of Science ®Google Scholar
• Satoh M, Hayashi H, Watanabe M, et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol. 2003;95(3):e111–e118.
   PubMedGoogle Scholar
• Lano G, Burtey S, Sallée M. Indoxyl sulfate, a uremic endotheliotoxin. Toxins. 2020;12(4):229.
   PubMed Web of Science ®Google Scholar
• Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. JASN. 2016;27(1):305–313.
   Web of Science ®Google Scholar
• Meijers BKI, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant. 2011;26(3):759–761.
   PubMed Web of Science ®Google Scholar
• Pluznick JL. Gut microbiota in renal physiology: focus on short-chain fatty acids and their receptors. Kidney Int. 2016;90(6):1191–1198.
   PubMed Web of Science ®Google Scholar
• Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. 2013;70(4):631–659.
   PubMed Web of Science ®Google Scholar
• Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol. 2010;298(6):G851–G859.
   PubMed Web of Science ®Google Scholar
• Lau WL, Savoj J, Nakata MB, et al. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clin Sci. 2018;132: 509–522.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Lu H, Zhu H, et al. A network-regulative pattern in the pathogenesis of kidney injury following severe acute pancreatitis. Biomed Pharmacother. 2020;125:109978.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ankawi G, Sun J, et al. Gut-kidney crosstalk in septic acute kidney injury. Crit Care. 2018;22(1):117.
   PubMedGoogle Scholar
• Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799–809.
   PubMed Web of Science ®Google Scholar
• Zahs A, Bird MD, Ramirez L, et al. Inhibition of long myosin light-chain kinase activation alleviates intestinal damage after binge ethanol exposure and burn injury. Am J Physiol Gastrointest Liver Physiol. 2012;303(6):G705–G712.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol. 2013;37(1):1–6.
   PubMed Web of Science ®Google Scholar
• Jang HR, Gandolfo MT, Ko GJ, et al. Early exposure to germs modifies kidney damage and inflammation after experimental ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2009;297(5):F1457–F1465.
   PubMed Web of Science ®Google Scholar
• Krebs CF, Paust H-J, Krohn S, et al. Autoimmune renal disease is exacerbated by S1P-Receptor-1-dependent intestinal Th17 cell migration to the kidney. Immunity. 2016;45(5):1078–1092.
   PubMed Web of Science ®Google Scholar
• Mehrotra P, Patel JB, Ivancic CM, et al. Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by at-1R antagonism. Kidney Int. 2015;88(4):776–784.
   PubMed Web of Science ®Google Scholar
• Yang J, Kim CJ, Go YS, et al. Intestinal microbiota controls acute kidney injury severity by immune modulation. Kidney Int. 2020;98(4):932–946.
   PubMed Web of Science ®Google Scholar
• Emal D, Rampanelli E, Stroo I, et al. Depletion of gut microbiota protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2017;28(5):1450–1461.
   PubMed Web of Science ®Google Scholar
• Andrade-Oliveira V, Amano MT, Correa-Costa M, et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol. 2015;26(8):1877–1888.
   PubMed Web of Science ®Google Scholar
• Souza DG, Vieira AT, Soares AC, et al. The essential role of the intestinal microbiota in facilitating acute inflammatory responses. J Immunol. 2004;173(6):4137–4146.
   PubMed Web of Science ®Google Scholar
• Andrade-Oliveira V, Foresto-Neto O, Watanabe IKM, et al. Inflammation in renal diseases: new and old players. Front Pharmacol. 2019;10:1192.
   PubMed Web of Science ®Google Scholar
• Senok AC, Ismaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect. 2005;11(12):958–966.
   PubMed Web of Science ®Google Scholar
• Di Cerbo A, Palmieri B, Aponte M, et al. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;69(3):187–203.
   PubMed Web of Science ®Google Scholar
• Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491–502.
   PubMed Web of Science ®Google Scholar
• Reid G. Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol. 2016;30(1):17–25.
   PubMed Web of Science ®Google Scholar
• Lee E-S, Song E-J, Nam Y-D, et al. Probiotics in human health and disease: from nutribiotics to pharmabiotics. J Microbiol (Seoul, Korea). 2018;56(11):773–782.
   PubMed Web of Science ®Google Scholar
• Tsai Y-L, Lin T-L, Chang C-J, et al. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3.
   PubMedGoogle Scholar
• García-Arroyo FE, Gonzaga G, Muñoz-Jiménez I, et al. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS ONE. 2018;13(8):e0202901.
   PubMed Web of Science ®Google Scholar
• Haro C, Mónaco ME, Medina M. Lactobacillus casei beneficially modulates immuno-coagulative response in an endotoxemia model. Blood Coagul Fibrinolysis. 2018;29(1):104–110.
   PubMed Web of Science ®Google Scholar
• Wanchai K, Yasom S, Tunapong W, et al. Probiotic Lactobacillus paracasei HII01 protects rats against obese-insulin resistance-induced kidney injury and impaired renal organic anion transporter 3 function. Clin Sci (Lond). 2018;132(14):1545–1563.
   PubMed Web of Science ®Google Scholar
• Lee T-H, Park D, Kim YJ, et al. Lactobacillus salivarius BP121 prevents cisplatin-induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p-cresol sulfate via alleviating dysbiosis. Int J Mol Med. 2020;45(4):1130–1140.
   PubMed Web of Science ®Google Scholar
• Lee Y-J, Li K-Y, Wang P-J, et al. Alleviating chronic kidney disease progression through modulating the critical genus of gut microbiota in a cisplatin-induced Lanyu pig model. J Food Drug Anal. 2020;28(1):103–114.
   PubMed Web of Science ®Google Scholar
• Vitetta L. Probiotics can break the toxic relationship between the intestinal microbiome and the kidney. Dig Dis Sci. 2019;64(2):297–299.
   PubMed Web of Science ®Google Scholar
• Simeoni M, Citraro ML, Cerantonio A, et al. An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD). Eur J Nutr. 2019;58(5):2145–2156.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang W, Zuo L, et al. Bifidobacteria may be beneficial to intestinal microbiota and reduction of bacterial translocation in mice following ischaemia and reperfusion injury. Br J Nutr. 2013;109(11):1990–1998.
   PubMed Web of Science ®Google Scholar
• Xing H-C, Li L-J, Xu K-J, et al. Protective role of supplement with foreign bifidobacterium and Lactobacillus in experimental hepatic ischemia-reperfusion injury. J Gastroenterol Hepatol. 2006;21(4):647–656.
   PubMed Web of Science ®Google Scholar
• Zhu H, Cao C, Wu Z, et al. The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease. Cell Metab. 2021;33(10):2091–2093.
   PubMed Web of Science ®Google Scholar
• Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200.
   PubMed Web of Science ®Google Scholar
• Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119.
   PubMed Web of Science ®Google Scholar
• Rossi M, Johnson DW, Xu H, et al. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutr Metab Cardiovas Dis. 2015;25(9):860–865.
   PubMed Web of Science ®Google Scholar
• Carney EF. Acute kidney injury. Protective role of gut microbial SCFAs. Nat Rev Nephrol. 2015;11(3):127.
   Google Scholar
• Felizardo RJF, Watanabe IKM, Dardi P, et al. The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids. Pharmacol Res. 2019;141:366–377.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Mikami D, Kimura H, et al. Short-chain fatty acids, GPR41 and GPR43 ligands, inhibit TNF-α-induced MCP-1 expression by modulating p38 and JNK signaling pathways in human renal cortical epithelial cells. Biochem Biophys Res Commun. 2017;486(2):499–505.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhou L, Guo H, et al. The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response. Metabolism. 2017;68:20–30.
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Nadeem A, Ahmad SF, et al. Short chain fatty acid, acetate ameliorates sepsis-induced acute kidney injury by inhibition of NADPH oxidase signaling in T cells. Int Immunopharmacol. 2018;58:24–31.
   PubMed Web of Science ®Google Scholar
• Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–276.
   PubMed Web of Science ®Google Scholar
• de las Casas-Engel M, Domínguez-Soto A, Sierra-Filardi E, et al. Serotonin skews human macrophage polarization through HTR2B and HTR7. JI. 2013;190(5):2301–2310.
   Google Scholar
• Fellows R, Varga-Weisz P. Chromatin dynamics and histone modifications in intestinal microbiota-host crosstalk. Mol Metab. 2020;38:100925.
   PubMed Web of Science ®Google Scholar
• Du Y, Tang G, Yuan W. Suppression of HDAC2 by sodium butyrate alleviates apoptosis of kidney cells in db/db mice and HG-induced NRK52E cells. Int J Mol Med. 2020;45(1):210–222.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li YJ, Loh YW, et al. Fiber derived microbial metabolites prevent acute kidney injury through G-Protein coupled receptors and HDAC inhibition. Front Cell Dev Biol. 2021;9:648639.
   PubMedGoogle Scholar
• Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040.
   PubMed Web of Science ®Google Scholar
• Jauregui-Amezaga A, Somers M, De Schepper H, et al. Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab. Clin Exp Gastroenterol. 2017;10:293–301.
   PubMed Web of Science ®Google Scholar
• Nirula A, Nilsen J, Klekotka P, et al. Effect of IL-17 receptor a blockade with brodalumab in inflammatory diseases. Rheumatology (Oxford). 2016;55(suppl 2):ii43–ii55.
   PubMedGoogle Scholar
• Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187.
   PubMed Web of Science ®Google Scholar
• de Smet AMGA, Kluytmans JAJW, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009;360(1):20–31.
   PubMed Web of Science ®Google Scholar
• Nazzal L, Roberts J, Singh P, et al. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease. Nephrol Dial Transplant. 2017;32(11):1809–1817.
   PubMed Web of Science ®Google Scholar
• Mu Q, Tavella VJ, Kirby JL, et al. Antibiotics ameliorate lupus-like symptoms in mice. Sci Rep. 2017;7(1):13675.
   PubMedGoogle Scholar
• Sánchez-Ramírez C, Hípola-Escalada S, Cabrera-Santana M, et al. Long-term use of selective digestive decontamination in an ICU highly endemic for bacterial resistance. Crit Care. 2018;22(1):141.
   PubMedGoogle Scholar
• Hiippala K, Jouhten H, Ronkainen A, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients. 2018;10(8):988.
   PubMed Web of Science ®Google Scholar
• Osada Y, Nakagawa S, Ishibe K, et al. Antibiotic-induced microbiome depletion alters renal glucose metabolism and exacerbates renal injury after ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol. 2021;321(4):F455–F465.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Yuan J, Khazaeli M, et al. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol. 2013;37(6):518–525.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Meijers BKI, Bammens BRM, et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int. 2009;76(114):S12–S19.
   PubMedGoogle Scholar
• Lin C-J, Sun C-Y, Wu C-J, et al. CharXgen-activated bamboo charcoal encapsulated in sodium alginate microsphere as the absorbent of uremic toxins to retard kidney function deterioration. IJMS. 2020;21(4):1257.
   Google Scholar
• Feng W, Ao H, Peng C, et al. Gut microbiota, a new frontier to understand traditional Chinese medicines. Pharmacol Res. 2019;142:176–191.
   PubMed Web of Science ®Google Scholar
• Sun J, Luo J-W, Yao W-J, et al. Effect of emodin on gut microbiota of rats with acute kidney failure. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2019;44(4):758–764.
   PubMedGoogle Scholar
• Han W-B, Liu Y-L, Wan Y-G, et al. Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of chinese herbal medicine. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2017;42(13):2425–2432.
   PubMedGoogle Scholar
• Gupta A, Khanna S. Fecal microbiota transplantation. JAMA. 2017;318(1):102.
   PubMedGoogle Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569–580.
   PubMed Web of Science ®Google Scholar
• Kelly CP. Fecal microbiota transplantation-an old therapy comes of age. N Engl J Med. 2013;368(5):474–475.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110–118.e114.
   PubMed Web of Science ®Google Scholar
• Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26(4):611–619.e616.
   PubMed Web of Science ®Google Scholar
• Hu ZB, Lu J, Chen PP, et al. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics. 2020;10(6):2803–2816.
   PubMed Web of Science ®Google Scholar
• Lauriero G, Abbad L, Vacca M, et al. Fecal microbiota transplantation modulates renal phenotype in the humanized mouse model of IgA nephropathy. Front Immunol. 2021;12:694787.
   PubMed Web of Science ®Google Scholar
• Zhao J, Bai M, Yang X, et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports. Ren Fail. 2021;43(1):928–933.
   PubMed Web of Science ®Google Scholar
• Barba C, Soulage CO, Caggiano G, et al. Effects of fecal microbiota transplantation on composition in mice with CKD. Toxins (Basel). 2020;12(12):741.
   PubMed Web of Science ®Google Scholar
• Venkatachalam MA, Weinberg JM, Kriz W, et al. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765–1776.
   PubMed Web of Science ®Google Scholar
• DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043–2050.
   PubMed Web of Science ®Google Scholar